Adherex Technologies, Inc. (AMEX: ADH), a biopharmaceutical company, is focused on discovering and developing novel cancer therapeutics. They currently have a number of products in the clinical stage of development, including eniluracil, ADH-1 and sodium thiosulfate (STS). Adherex’s mission is to become a leading developer of innovative treatments that address important unmet medical needs in cancer. For further information, visit the Company’s web site at www.adherex.com.
- 17 years ago
QualityStocks
Adherex Technologies, Inc. (AMEX: ADH)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Prices $344.4 Million in PIPEs to Launch Digital Asset Treasury Strategy
Predictive Oncology (NASDAQ: POAI) announced the pricing of two concurrent private placement transactions totaling approximately…
-
QualityStocksNewsBreaks – Massimo Group (NASDAQ: MAMO) Unveils 2026 MVR Series With First HVAC-Equipped Electric Carts
Massimo Group (NASDAQ: MAMO) announced the launch of its 2026 MVR Series, introducing the MVR HVAC…
-
QualityStocksNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Expands European Medical Advisory Board to Advance HyBryte Phase 3 Study
Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on treatments for rare diseases, announced the…